J — Jacobs Solutions Inc.

The fundamental news flow is unambiguously positive: Q3 FY2026 (reported 2026-08-04) gross revenue of $4.1B (+34.5% y/y), adjusted EPS of $1.84 vs $1.83 consensus, a record $28.9B backlog (+27.3% y/y), AI/data-center work at 11% of adjusted net revenue, and FY26 adjusted EPS guidance raised for the third consecutive quarter. Sell-side sentiment matches — consensus is Buy (24 Buy / 14 Hold / 0 Sell) with a recent average target of $163.14, ~15% above the 2026-09-13 price of $141.85. But the market's own verdict disagrees: the stock is -3.0% over the past week and -2.42% over the past month, sits 3.43% below its 20-day SMA and 16% under its 52-week high despite that beat-and-raise. That divergence — great news, flat-to-down price — is why sentiment reads Neutral rather than Bullish: the good news appears largely priced, and traders are taking profits into it.

Strip out the 2024-09-27 quarter (revenue shown as -$1.159B, a reclassification artifact tied to the Critical Mission Solutions/Amentum separation that also shows up as the deterministic score's warning note), and the underlying trend is clean and accelerating. Sequential gross revenue: $2,910M (Q2 FY25) → $3,029M (+4.1%) → $3,155M (+4.1%) → $3,293M (+4.4%) → $3,695M (+12.2%) → $4,076M (+10.3%) in Q3 FY26. YoY went from +12.3% (Q1 FY26) to +26.9% (Q2 FY26) to +34.5% (Q3 FY26) — that is genuine acceleration, not a blip, and it is backed by a $28.9B backlog. The catch is revenue quality: Q3 FY26 gross margin fell to 19.9% ($811M) from 25.3% ($767M) a year earlier, and operating margin compressed to 7.0% ($287M) from 8.4% ($255M) — the incremental revenue is heavily low-margin pass-through/procurement content from large advanced-facilities programs, which is why gross revenue grew 34.5% while adjusted net revenue grew only 8.3%. GAAP earnings remain noisy (Q2 FY26 posted a -$81M operating loss and -$0.34 EPS), while adjusted EPS and guidance march up. Cash is respectable but lagging the ramp: Q2 FY26 operating cash flow was -$484M versus -$96M a year earlier, though the accruals ratio of -2.72% (cash ahead of accounting earnings) and TTM OCF of ~$736M versus ~$335M of GAAP net income confirm earnings aren't being manufactured.

As of 2026-09-13 at $141.85, the headline numbers are contradictory and the contradiction matters. Trailing GAAP P/E is 49.4x versus a 5-year average of 31.3x — superficially 'Rich vs. its own history.' But TTM GAAP EPS of $2.82 is depressed by the -$0.34 Q2 FY26 quarter and by non-cash PA Consulting intangible amortization; against FY2027 consensus EPS of $7.256 the forward P/E is only 19.6x, below the company's own historical average and roughly in line with engineering/consulting peers. Price/sales of 1.18x is actually below the 5-year average of 1.28x, and the screener's trailing EV/EBITDA of 21.9x becomes roughly 13x on FY2026E adjusted EBITDA (~$1.45B) versus a ~$19.2B enterprise value. Verdict: fair-to-slightly-full on the adjusted earnings that management and the Street actually underwrite; expensive only on a GAAP basis that most buyers ignore. There is no deep-value cushion here, but it is not a bubble either.

The stock is not being paid for growth it has already booked. Management has raised FY26 adjusted EPS guidance three times and reported a record backlog, yet J trades 16% below its 52-week high and is down over the past month — the multiple is compressing even as estimates rise, which is the classic setup where the market doubts durability (AI capex sustainability, pass-through-flattered revenue, leverage). The flip side: at 19.6x forward adjusted EPS, the stock is also not discounting the possibility that FY27 consensus of $7.256 is simply stale (it is essentially flat versus FY26 guidance of $7.20–7.30 despite a +27% backlog), which means mid-teens FY27 growth would look like an earnings revision cycle the price hasn't captured. Practical playbook: treat headline GAAP P/E (49x) as noise, watch adjusted EPS guidance and net-revenue growth (not gross), and treat free-cash-flow conversion as the confirmation signal — if the revenue ramp starts converting to cash at the normal seasonal pace, the multiple has room to re-rate; if working capital keeps absorbing it (Q2 FY26 OCF of -$484M), the market's skepticism is justified.

As of 2026-09-13, J is in a short-term pullback inside a medium-term uptrend. RSI(14) of 44.53 is neutral-to-soft — neither oversold nor overbought, so no mean-reversion signal in either direction. Price sat 3.43% below the 20-day SMA (~$147), 1.45% above the 50-day SMA (~$140), and 6.82% above the 200-day SMA (~$133). Momentum: -3.0% one week, -2.42% one month, +11.69% three months, +10.77% six months — a consolidating pause after a strong spring/summer run, with beta of 0.679 meaning it should move less than the index on both sides. Entry-timing implication: this is not a chase point. The 50-day (~$140) is being tested right now; losing it opens the low-$130s (200-day) where risk/reward improves materially, while reclaiming ~$147–$150 would confirm the pullback was noise. Buying strength above $150 or weakness near $133 are both better spots than $142 in no-man's-land.

• Hyperscaler AI/data-center capital expenditure cycle — the single biggest swing factor; direct AI data center and infrastructure work is now 11% of adjusted net revenue, with life sciences and advanced manufacturing growing 24% organically. Any digestion pause by a few mega-cap customers hits both backlog conversion and the multiple.
• US and UK public infrastructure spending — water/wastewater modernization (Oklahoma City), grid and energy storage (UK MESH), and transit programs (MetroLink JV with AECOM) are federally or municipally funded and less rate-sensitive, but exposed to budget cycles, continuing resolutions, and program timing slippage.
• Interest rates and financing conditions — sticky rates pressure commercial real estate and private development, while mission-critical facilities (semiconductors, life sciences, data centers) are largely corporate- or PE-funded and comparatively insulated; J's own cost of capital matters given long-term debt rose to $3.58B.
• Sector rotation in and out of AI-adjacent industrials — J trades as a 'picks-and-shovels AI' name, so sentiment on AI capex sustainability can move the stock independently of its own results, as the flat month-on-beat-and-raise shows.
• Technical labor cost inflation and materials pass-through — professional/engineering talent is scarce and wage inflation is structural for a labor-based model, while steel and equipment cost inflation flows through low-margin pass-through revenue lines, further diluting reported margins.

• Fiscal Q4 and full-year FY2026 earnings (late November/early December 2026) — the first read on FY2027 guidance, and the single biggest test of whether the $7.20–7.30 FY26 adjusted EPS and mid-teens growth trajectory carry forward.
• Backlog and bookings updates in AI data centers, semiconductors, and life sciences — the $28.9B backlog (+27.3% y/y) only helps if it keeps converting, and further record bookings would validate the growth story the stock is not fully pricing.
• Capital returns: $614M of buybacks already executed YTD through Q3 FY26 (roughly 3.7% of market cap) plus a 0.93% dividend yield with room to grow — a shrinking share count mechanically lifts per-share metrics and supports the forward P/E math.
• PA Consulting integration and the $20M+ cost-synergy program targeted within 24 months — successful delivery would widen margins at the higher-value consulting end and help close the GAAP-to-adjusted earnings gap.
• Any sign of GAAP earnings convergence (lower intangible amortization, no repeat of the Q2 FY26 -$81M operating loss quarter) — that would collapse the punitive 49x trailing P/E toward the 20x range and remove a persistent overhang.

• The GAAP-to-adjusted earnings chasm — TTM GAAP EPS of $2.82 versus FY26 adjusted guidance of $7.20–7.30 is a very wide bridge, driven by intangible amortization and one-offs such as the Q2 FY26 operating loss of -$81M. If charges recur or GAAP results miss, the 49x headline multiple gives the stock enormous downside torque.
• Leverage has jumped meaningfully — long-term debt went from $2.49B (2025-12-26) to $4.08B (2026-03-27) to $3.58B (2026-06-26) against only $1.17B of cash, with debt/equity at 1.24 and long-term debt/equity at 1.10. The March spike coincided with a -$484M quarterly operating cash outflow, so the working-capital and financing risks are linked.
• Revenue quality deterioration — gross margin fell to 19.9% in Q3 FY26 from 25.3% a year earlier as low-margin pass-through revenue inflates gross revenue; the 34.5% headline growth overstates the profitability actually being added, and if the mix never normalizes, margins and EPS estimates get revised down.
• Concentration in the AI/data-center capex cycle — 11% of adjusted net revenue is directly AI-related and 24% organic growth in advanced facilities/life sciences means the incremental growth is concentrated in the most sentiment-sensitive end market; a hyperscaler capex reset would hit backlog conversion and the multiple simultaneously.
• Cash conversion lag — Q2 FY26 operating cash flow of -$484M versus -$96M in the prior-year quarter, and only ~$291M of 9-month FY26 free cash flow, means the revenue ramp is tying up working capital; sustained failure to convert growth into cash undermines buybacks, deleveraging, and the quality score.
• Public-sector program timing and integration execution — municipal and UK government awards (MESH, MetroLink, Oklahoma City water) can slip on political or funding calendars, and delivering PA Consulting synergies while retaining scarce technical talent is not guaranteed.

Jacobs is a genuinely good business having a genuinely good run — a record $28.9B backlog, three consecutive guidance raises, real leverage to AI/data-center and advanced-facilities build-out, and a forward P/E of ~19.6x that is below its own historical average. But at $141.85 on 2026-09-13 there is no margin of safety: gross margin is compressing because the fastest-growing revenue is pass-through, long-term debt nearly doubled over six months to $3.58B, cash conversion is lagging the revenue ramp, and the stock is down over the past month despite a beat-and-raise — the market is telling you the good news is priced. This is an accumulate-on-weakness name (low-$130s near the 200-day SMA is a materially better risk/reward than here), not a buy-at-any-price compounder, and it deserves position sizing that respects the wide GAAP-versus-adjusted earnings gap.

Applied a 21x justified forward P/E (roughly 1.4x PEG on mid-teens adjusted EPS growth, in line with engineering/consulting peers such as AECOM and EMCOR and below Jacobs' own 5-year average trailing GAAP P/E of 31.3x once the amortization/one-off distortion is stripped out) to FY2027 consensus EPS of $7.256, giving 21.0 x $7.256 = $152.38. Cross-check: ~13x EV/EBITDA on ~$1.45B of FY2027E adjusted EBITDA against ~$2.4B of net debt implies roughly $146, so $152 sits in the upper-middle of my method band — ~7% above the 2026-09-13 price of $141.85 but below the $165.14 sell-side consensus, a gap I'm comfortable with because FY27 consensus EPS looks stale (flat versus FY26 guidance of $7.20–7.30) and mid-teens growth would push the same multiple toward the mid-$170s.